Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, has established its Global Headquarters in Singapore. This announcement is supported by the Singapore Economic Development Board (EDB) and the company is backed by The Sylvan Group, an independent private equity investment firm focused on deep value companies with strong ESG-compliance. 

Juniper Biologics aims to build a patient-centric presence throughout key markets in Singapore and around the globe. The unit is set to carry out a full range of activities for its fast-growing international business for its portfolio of medicines in oncology and oncology supportive care, rare diseases and gene therapy, with a goal of expanding access of its pharmaceutical portfolio to patients across the emerging markets.

The facility is furnished with active management and coordination around medical affairs, regulatory affairs, commercial and business development as well as all finance and invoicing activities.    

“Singapore is an excellent hub for Juniper Biologics to base our global operations. Our goal is to bring the next generation of medicines to patients throughout the region and beyond,” said Raman Singh, Chief Executive Officer of Juniper Biologics.